English
Spanish
Italian
French
Greek
Portuguese
Japanese
Danish
Dutch
Finnish
Croatian
Estonian
Filipino
Czech
Korean
Slovenian
Chinese (Simplified)
Chinese (Traditional)
Somali
Hebrew
Polish
Hindi
Hungarian
Slovak
Norwegian
Swedish
Persian
Romanian
Punjabi
Arabic
Ukrainian
Russian
Bulgarian
Indonesian
Bosnian
Afrikaans
Armenian
AlbanianJapanese drugmaker Eisai reported Monday the first U.S. sales of Leqembi, its treatment for Alzheimer’s disease, although exact numbers were not provided and people taking the drug appear to be paying out of pocket because insurance coverage has not yet been established.
The first U.S. sales of Leqembi were recorded on Jan. 18, Eisai said Monday during its presentation of financial results for the fiscal third quarter that ended on Dec. 31.
Continue to STAT+ to read the full story…
Click this link for the original source of this article.
Author: Adam Feuerstein
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
